Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$7.60 USD

7.60
266,218

-0.04 (-0.52%)

Updated Sep 18, 2024 04:00 PM ET

After-Market: $7.60 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ANGO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for AngioDynamics, Inc falls in the month of May.

All items in Millions except Per Share data.

5/31/2024 5/31/2023 5/31/2022 5/31/2021 5/31/2020
Assets          
Cash & Equivalents 76 45 29 48 54
Receivables 44 53 52 35 31
Notes Receivable 0 0 0 0 0
Inventories 61 55 51 49 60
Other Current Assets 13 11 11 9 7
Total Current Assets 193 164 143 141 153
Net Property & Equipment 36 44 45 37 28
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 77 270 353 370 398
Deposits & Other Assets 11 54 11 13 15
Total Assets 318 533 553 561 594
Liabilities & Shareholders Equity 5/31/2024 5/31/2023 5/31/2022 5/31/2021 5/31/2020
Notes Payable 0 0 0 0 0
Accounts Payable 38 40 28 20 19
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 41 27 35 35 29
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 12 17 11 3 3
Total Current Liabilities 91 84 74 58 51
Mortgages 0 0 0 0 0
Deferred Taxes/Income 5 13 16 20 24
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 50 25 20 40
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 16 8 13 24 24
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 112 154 128 122 139
Shareholders Equity 5/31/2024 5/31/2023 5/31/2022 5/31/2021 5/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 610 599 587 574 562
Retained Earnings -395 -211 -158 -132 -100
Other Equity -4 -5 1 3 -1
Treasury Stock 6 6 6 6 6
Total Shareholder's Equity 206 378 424 439 455
Total Liabilities & Shareholder's Equity 318 533 553 561 594
Total Common Equity 206 378 424 439 455
Shares Outstanding 40.00 39.20 38.70 38.10 37.60
Book Value Per Share 5.14 9.65 10.97 11.53 12.10

Fiscal Year End for AngioDynamics, Inc falls in the month of May.

All items in Millions except Per Share data.

8/31/2024 5/31/2024 2/29/2024 11/30/2023 8/31/2023
Assets          
Cash & Equivalents -99,999 76 78 61 58
Receivables NA 44 49 52 50
Notes Receivable NA 0 0 0 0
Inventories NA 61 58 64 60
Other Current Assets NA 13 11 9 8
Total Current Assets NA 193 197 185 175
Net Property & Equipment NA 36 37 43 43
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 77 82 263 266
Deposits & Other Assets NA 11 9 8 9
Total Assets NA 318 325 500 494
Liabilities & Shareholders Equity 8/31/2024 5/31/2024 2/29/2024 11/30/2023 8/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 38 35 38 25
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 41 31 29 26
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 12 20 11 7
Total Current Liabilities NA 91 86 78 57
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 5 6 18 1
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 14 3 7
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 112 106 98 66
Shareholders Equity 8/31/2024 5/31/2024 2/29/2024 11/30/2023 8/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 610 609 605 604
Retained Earnings NA -395 -382 -194 -165
Other Equity NA -4 -3 -5 -6
Treasury Stock NA 6 6 6 6
Total Shareholder's Equity NA 206 219 401 428
Total Liabilities & Shareholder's Equity NA 318 325 500 494
Total Common Equity 0 206 219 401 428
Shares Outstanding 40.20 40.00 39.80 39.80 39.80
Book Value Per Share 0.00 5.14 5.49 10.08 10.75